What is claimed is:

1. A method for treating disease in a patient in need of treatment comprising administering to the patient a dosage form providing once-daily oral administration of *d-threo*-methylphenidate hydrochloride, said dosage form comprising two groups of particles, each containing *d-threo*-methylphenidate, wherein:

a) said first group of particles comprises from about 2% to about 99% by weight of *d-threo*-methylphenidate hydrochloride and provides a substantially immediate dose of said *d-threo* methylphenidate upon ingestion by a mammal; and

b) said second group of particles comprises coated particles, said coated particles comprising from about 2% to about 75% by weight of *d-threo*-methylphenidate in admixture with one or more binders, and a coating consisting of an ammonio methacrylate copolymer in an amount sufficient to provide a dose of said *d-threo*-methylphenidate hydrochloride delayed by from about 4 hours to about 7 hours following said ingestion.

2. A dosage form of a pharmaceutically acceptable salt of a methylphenidate providing an *in vitro* release profile comprising two pulses of drug release, wherein said pulses are temporally separated by from about two hours to about seven hours.

3. A dosage form of a pharmaceutically acceptable salt of a methylphenidate providing a *in vitro* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.